TABLE 1.

Reactogenicity of nasal and intramuscular immunizations

Symptom	No. of subjects with symptom or % of groupa
	1st immunization					2nd immunization
	i.m.	Nasal				Nasal
		Naive		Ipsilateral preimmunized	% of whole group	Naive		Ipsilateral preimmunized	% of whole group
		Contralateral	Ipsilateral			Contralateral	Ipsilateral
Injection site pain	4				66
Mild	4				66
Nasal discharge		3	4	6	48	0	1	4	19
Mild		2	2	6	19	0	1	4	19
Moderate		1	2	0	11	0	0	0	0
Nasal discomfort		0	3	3	22	1	2	4	26
Mild		0	1	2	11	0	1	3	15
Moderate		0	2	1	11	1	1	1	11
Nasal congestion		2	0	5	26	1	1	3	19
Mild		2	0	5	26	1	1	2	15
Moderate		0	0	0	0	0	0	1	4
Headache		2	4	2	30	1	1	4	22
Mild		0	3	1	15	0	1	1	7
Moderate		1	1	1	11	1	0	3	15
Severe		1	0	0	4	0	0	0	0
Sneezing		2	1	1	15	0	1	1	7
Mild		1	0	1	7	0	1	1	7
Moderate		1	1	0	7	0	0	0	0
Sore throat		0	1	0	4	1	1	0	7
Mild		0	1	0	4	0	1	0	4
Moderate		0	0	0	0	1	0	0	4
Itchy nose		1	1	0	7	0	1	0	4
Mild		0	1	0	4	0	1	0	4
Moderate		1	0	0	4	0	0	0	0
Watery eyes		1	0	0	4	2	0	0	7
Mild		0	0	0	0	1	0	0	4
Moderate		1	0	0	4	1	0	0	4
Eye pain		0	1	1	7	0	0	0	0
Mild		0	1	1	7	0	0	0	0
Severe		0	0	0	0	0	0	0	0

^aNumber of subjects recording symptoms on the diary card during 28 days after each immunization other than those designated as “unrelated” or “remote” relationship to immunization. Subjects may have had more than one occurrence of any symptom during this time but are counted only once. Row percentages are calculated for the 27 subjects in the nasal group and 6 subjects in the intramuscular (i.m.) groups. Severity grades were omitted if no subjects reported symptoms of that grade.